Halozyme Therapeutics Inc. is a biopharmaceutical company. The Company’s research focuses on human enzymes that alter the extracellular matrix. The Company’s proprietary pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. The product candidates in its pipeline are based on rHuPH20, a patented human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA), a naturally occurring substance that is a component of the extracellular matrix in tissues throughout the body, such as skin and cartilage. The Company has collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Pfizer Inc. (Pfizer), Baxter Healthcare Corporation (Baxter) and Intrexon Corporation (Intrexon), with approximately two approved products for marketing in Europe. The Company’s products include Hylenex Recombinant, Ultrafast Insulin Program, PEGPH20 and HTI-501.